The Intersection of Maternal Metabolic Syndrome, Adverse Pregnancy Outcomes, and Future Metabolic Health for the Mother and Offspring.

Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101150318 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8518 (Electronic) Linking ISSN: 15404196 NLM ISO Abbreviation: Metab Syndr Relat Disord Subsets: MEDLINE

Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c2003-

Diabetes, Gestational* ; Metabolic Syndrome*/complications ; Metabolic Syndrome*/diagnosis ; Metabolic Syndrome*/epidemiology ; Pregnancy Complications*/diagnosis ; Pregnancy Complications*/epidemiology; Female ; Humans ; Mothers ; Obesity/complications ; Obesity/epidemiology ; Obesity/therapy ; Pregnancy ; Pregnancy Outcome/epidemiology ; Risk Factors

The prevalence of obesity is ∼40% in the United States, and the prepregnancy prevalence of obesity in females is ∼30%. This has in part fueled an increase in metabolic syndrome (MetS) among females who are currently pregnant, have been pregnant, or are planning to become pregnant. Importantly, MetS in pregnancy is associated with increased pregnancy complications. Moreover, MetS in pregnancy may have long-lasting adverse cardiovascular and metabolic health implications for the mother and her offspring. To complicate matters, many adverse pregnancy outcomes seem to increase the risk of MetS in the mother after pregnancy. Herein, we describe the potential mechanisms behind the intersection of MetS, adverse pregnancy outcomes, and subsequent long-term disease in the mother and offspring. Because MetS is a cluster of coexisting conditions, it is challenging to identify mediators that can serve as biomarkers for early diagnosis and targets for MetS prevention and therapy.

JAMA. 2013 Jun 12;309(22):2362-70. (PMID: 23757084)
Obes Facts. 2020;13(2):237-244. (PMID: 32222705)
Am J Cardiol. 2006 Jan 16;97(2A):3A-11A. (PMID: 16442931)
Adv Exp Med Biol. 2018;1065:455-470. (PMID: 30051401)
Annu Rev Physiol. 2012;74:107-30. (PMID: 21910625)
Rev Obstet Gynecol. 2008 Fall;1(4):170-8. (PMID: 19173021)
Int J Mol Sci. 2021 Apr 14;22(8):. (PMID: 33919834)
Diabetologia. 2019 Jun;62(6):905-914. (PMID: 30843102)
J Obstet Gynaecol Can. 2005 Dec;27(12):1095-101. (PMID: 16524527)
Diabetes Care. 2007 Aug;30(8):2070-6. (PMID: 17416786)
PLoS Med. 2018 Dec 4;15(12):e1002710. (PMID: 30513077)
Obes Rev. 2010 May;11(5):354-61. (PMID: 19793375)
N Engl J Med. 2008 Jul 3;359(1):61-73. (PMID: 18596274)
Obstet Gynecol Sci. 2019 Jul;62(4):233-241. (PMID: 31338340)
Diabetes. 2016 Aug;65(8):2214-23. (PMID: 27217482)
PLoS One. 2017 Jan 26;12(1):e0169223. (PMID: 28125591)
Am J Clin Nutr. 2017 Jan;105(1):3-4. (PMID: 28003208)
Am J Physiol Regul Integr Comp Physiol. 2017 Apr 1;312(4):R485-R491. (PMID: 28122721)
Placenta. 2011 Mar;32(3):247-54. (PMID: 21232790)
Obstet Gynecol. 2020 Mar;135(3):634-643. (PMID: 32028483)
Nat Clin Pract Endocrinol Metab. 2007 Oct;3(10):696-704. (PMID: 17893688)
Endocr Connect. 2018 May;7(5):E1-E4. (PMID: 29712720)
Hypertension. 2018 Mar;71(3):491-498. (PMID: 29437895)
Front Cell Infect Microbiol. 2020 May 15;10:188. (PMID: 32500037)
Pediatrics. 2013 Apr;131(4):e1240-63. (PMID: 23509172)
BMJ. 2020 May 13;369:m1361. (PMID: 32404325)
Front Endocrinol (Lausanne). 2020 Nov 30;11:611929. (PMID: 33424775)
Int J Cardiol. 2019 Sep 15;291:158-167. (PMID: 31151766)
Nutrients. 2020 Apr 14;12(4):. (PMID: 32295104)
JCI Insight. 2018 Apr 19;3(8):. (PMID: 29669946)
Diabetol Metab Syndr. 2015 May 12;7:43. (PMID: 26893617)

Keywords: gestational diabetes; metabolic syndrome; placenta; pre-eclampsia; pregnancy

Date Created: 20220406 Date Completed: 20220620 Latest Revision: 20230602

20240105

PMC9360170

10.1089/met.2021.0124

35384734